Tartaric acid Tylenomycin premix belongs to the macrolide class of animal specific antibiotics, which inhibit the synthesis of bacterial proteins and thus inhibit bacterial reproduction. Its antibacterial spectrum is similar to that of Tylosin, and it has strong antibacterial effects on Staphylococcus aureus (including penicillin resistant strains), pneumococcus, streptococcus, anthrax bacteria, porcine erysipelas, Listeria monocytogenes, Clostridium putrescens, and Clostridium aeruginosa. This product is effective against Gram positive bacteria that are resistant to other antibiotics, and has almost no effect on Gram negative bacteria. It has strong antibacterial activity against Chlamydia septicemia and Mycoplasma synovialis. Bacteria are less likely to develop resistance to this product.

Tylenomycin  is a third-generation macrolide drug specifically designed for animals, the only drug that can truly reach the lumen of the bronchi and kill mycoplasma. Its antibacterial potency is 5-10 times that of Taiwanmycin and 2-5 times that of Timicozin; Alkaline side chains can effectively change the intracellular pH value and inhibit the proliferation of blue ear disease virus. Used for the prevention and treatment of mycoplasma diseases in livestock and poultry (such as porcine wheezing disease and chronic wheezing in chickens), porcine blue ear disease, porcine proliferative enteritis, infectious pleuropneumonia, and streptococcal disease.